Rubicon Research IPO Allotment Status: Check Overall Subscription & Steps to Verify Status

The subscription window for the Rubicon Research IPO closed yesterday, on October 13, 2025. The allotment process for Rubicon Research is expected to be finalised today, on October 14, 2025, and the company’s shares will be listed on both BSE and NSE. The tentative listing date is fixed as October 16, 2025.

Procedure to Check Rubicon Research IPO Allotment Status Online On BSE

• Click here to visit the application status page. 
• In Issue Type, select “Equity”.
• In Issue Name, select “Rubicon Research Ltd”.
• Enter your “Application No.” or “PAN No.”
• Click on “I am not a robot”.
• Click “Submit”.

Procedure to Check Rubicon Research IPO Allotment Status Online on NSE

• Visit the NSE’s IPO allotment verification status page here. 
• Select “Equity & SME IPO bid details”.
• In Select Symbol, select “Rubicon Research Ltd”.
• Enter your PAN No. and application No. 
• Click “Submit”.

Procedure to Check  Rubicon Research IPO Allotment Status on MUFG Intime India Private Limited (Registrar to the issue)

• Click here to visit MUFG Intime’s application status page. 
• Under, Please select company, select “Rubicon Research Ltd”.
• Enter any of the following details. 
• PAN
• App. No.
• DP/Client ID  
• Account No / IFSC
• Click “Submit”.

Rubicon Research IPO Overall Subscription Status

[October 13, 2025, end of the day]

On Day 3, the Rubicon Research IPO was subscribed 109.35 times. The public issue was subscribed 37.40 times by the Retail Individual Investors (RIIs), 102.70 times by the Non-Institutional Investors (NIIs), 17.68 times by the Employees and 137.09 times by the Qualified Institutional Buyers (QIBs).

Check out newly Listed IPOs on BSE and NSE.

Rubicon Research Ltd - IPO Details

Rubicon Research IPO was a bookbuilding of ₹1,377.50 crores. The issue was a combination of fresh issue of 1.03 crore shares aggregating to ₹500.00 crores and offer for sale of 1.81 crore shares aggregating to ₹877.50 crores. The issue price band was set at ₹461 to ₹485 per share. The minimum lot size for an application was 30, and the minimum amount required for a retail investor was ₹13,830 (30 shares).

Axis Capital Limited, IIFL Capital Services Limited (formerly known as IIFL Securities Limited), JM Financial Limited and SBI Capital Markets Limited were the book-running lead managers for the issue. MUFG Intime India Private Limited (formerly Link Intime India Private Limited) was the registrar for the Rubicon Research IPO.

Explore other Upcoming IPOs on BSE and NSE.

About Rubicon Research Ltd

Rubicon Research Ltd is an IP-led speciality pharmaceuticals company, founded in 1999 and based in Thane, India. It focuses on developing, manufacturing and commercialising value-added formulations for regulated markets (especially the US). Its product portfolio spans multiple dosage forms — oral solids, liquids, nasal & inhalation, ophthalmic, topical, injectables, and drug-device combinations. It operates R&D centres in Thane (India) and Concord (Canada), and has manufacturing plants in Ambernath and Satara (India).

Financially, in FY 2025, Rubicon Research reported total income of about ₹1,296.2 crore (up by 48.5% from ₹872.4 crore in FY 2024) and a Profit After Tax (PAT) of ₹134.36 crore, compared to ₹91.01 crore in FY 2024. Its EBITDA rose to ₹267.9 crore with margins improving to 20.7%.

Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory. 

To read the RA disclaimer, please click here.